08.05.2017 | Preclinical study | Ausgabe 2/2017

Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3

Zeitschrift:: Breast Cancer Research and Treatment > Ausgabe 2/2017

Autoren:: Brittany Turner-Ivey, Ericka L. Smith, Alex C. Rutkovsky, Laura S. Spruill, Jamie N. Mills, Stephen P. Ethier

» Jetzt Zugang zum Volltext erhalten

Wichtige Hinweise

Brittany Turner-Ivey and Ericka L. Smith have contributed equally to this work.

Abstract

Purpose

NSD3 has been implicated as a candidate driver oncogene from the 8p11-p12 locus, and we have previously published evidence for its amplification and overexpression in human breast cancer. This aim of this study was to further characterize the transforming function of NSD3 in vivo.

Methods

We generated a transgenic mouse model in which NSD3 gene expression was driven by the MMTV promoter and expressed in mammary epithelium of FVB mice. Mammary glands were fixed and whole mounts were stained with carmine to visualize gland structure. Mammary tumors were formalin-fixed, and paraffin embedded (FFPE) tumors were stained with hematoxylin and eosin.

Results

Pups born to transgenic females were significantly underdeveloped compared to pups born to WT females due to a lactation defect in transgenic female mice. Whole mount analysis of the mammary glands of transgenic female mice revealed a profound defect in functional differentiation of mammary gland alveoli that resulted in the lactation defect. We followed parous and virgin NSD3 transgenic and control mice to 50 weeks of age and observed that several NSD3 parous females developed mammary tumors. Whole mount analysis of the mammary glands of tumor-bearing mice revealed numerous areas of mammary hyperplasia and ductal dysplasia. Histological analysis showed that mammary tumors were high-grade ductal carcinomas, and lesions present in other mammary glands exhibited features of alveolar hyperplasia, ductal dysplasia, and carcinoma in situ.

Conclusions

Our results are consistent with our previous studies and demonstrate that NSD3 is a transforming breast cancer oncogene.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

★ PREMIUM-INHALT

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Bis zum 22.10. bestellen und 100 € sparen!

Jetzt gratis testen * Jetzt kaufen

Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

e.Med Gynäkologie & Urologie

Kombi-Abonnement

Mit e.Med Gynäkologie & Urologie erhalten Sie Zugang zu CME-Fortbildungen der beiden Fachgebiete, den Premium-Inhalten der Fachzeitschriften, inklusive einer gedruckten gynäkologischen oder urologischen Zeitschrift Ihrer Wahl.

Nicht verpassen: e.Med bis 22. Oktober 100 € günstiger.

Jetzt testen ¹

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Nicht verpassen: e.Med bis 22. Oktober 100 € günstiger.

Jetzt testen ²

Adelaide J, Chaffanet M, Imbert A, Allione F, Geneix J, Popovici C, van Alewijk D, Trapman J, Zeillinger R, Borresen-Dale AL et al (1998) Chromosome region 8p11-p21: refined mapping and molecular alterations in breast cancer. Genes Chromosomes Cancer 22(3):186–199 CrossRefPubMed

Ray ME, Yang ZQ, Albertson D, Kleer CG, Washburn JG, Macoska JA, Ethier SP (2004) Genomic and expression analysis of the 8p11–12 amplicon in human breast cancer cell lines. Cancer Res 64(1):40–47 CrossRefPubMed

Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Borresen-Dale AL, Levine AJ, Bhanot G et al (2012) Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. PLoS ONE 7(6):e38575 CrossRefPubMedPubMedCentral

Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, Letessier A, Ginestier C, Monville F et al (2005) Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 3(12):655–667 CrossRefPubMed

Carapeti M, Aguiar RC, Watmore AE, Goldman JM, Cross NC (1999) Consistent fusion of MOZ and TIF2 in AML with inv (8) (p11q13). Cancer Genet Cytogenet 113(1):70–72 CrossRefPubMed

Stec I, den Dunnen JT (2001) WHSC1L1, on human chromosome 8p11.2, closely resembles WHSC1 and maps to a duplicated region shared with 4p16.3. Genomics 76(1–3):5–8 CrossRefPubMed

Cully M, Shiu J, Piekorz RP, Muller WJ, Done SJ, Mak TW (2005) Transforming acidic coiled coil 1 promotes transformation and mammary tumorigenesis. Cancer Res 65(22):10363–10370 CrossRefPubMed

Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS (2007) FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9(2):R23 CrossRefPubMedPubMedCentral

Streicher KL, Yang ZQ, Draghici S, Ethier SP (2007) Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon. Oncogene 26(14):2104–2114 CrossRefPubMed

10.

Bernard-Pierrot I, Gruel N, Stransky N, Vincent-Salomon A, Reyal F, Raynal V, Vallot C, Pierron G, Radvanyi F, Delattre O (2008) Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 68(17):7165–7175 CrossRefPubMed

11.

Zhang J, Liu X, Datta A, Govindarajan K, Tam WL, Han J, George J, Wong C, Ramnarayanan K, Phua TY et al (2009) RCP is a human breast cancer-promoting gene with Ras-activating function. J Clin Invest 119(8):2171–2183 PubMedPubMedCentral

12.

Slorach EM, Chou J, Werb Z (2011) Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev 25(5):471–484 CrossRefPubMedPubMedCentral

13.

Wang G, Liu G, Wang X, Sethi S, Ali-Fehmi R, Abrams J, Zheng Z, Zhang K, Ethier S, Yang ZQ (2012) ERLIN2 promotes breast cancer cell survival by modulating endoplasmic reticulum stress pathways. BMC Cancer 12:225 CrossRefPubMedPubMedCentral

14.

Turner-Ivey B, Guest ST, Irish JC, Kappler CS, Garrett-Mayer E, Wilson RC, Ethier SP (2014) KAT6A, a chromatin modifier from the 8p11-p12 amplicon is a candidate oncogene in luminal breast cancer. Neoplasia 16(8):644–655 CrossRefPubMedPubMedCentral

15.

Yang ZQ, Liu G, Bollig-Fischer A, Giroux CN, Ethier SP (2010) Transforming properties of 8p11-12 amplified genes in human breast cancer. Cancer Res 70(21):8487–8497 CrossRefPubMedPubMedCentral

16.

Irish JC, Mills JN, Turner-Ivey B, Wilson RC, Guest ST, Rutkovsky A, Dombkowski A, Kappler CS, Hardiman G, Ethier SP (2016) Amplification of WHSC1L1 regulates expression and estrogen-independent activation of ERalpha in SUM-44 breast cancer cells and is associated with ERalpha over-expression in breast cancer. Mol Oncol 10:850–865 CrossRefPubMedPubMedCentral

17.

Angrand PO, Apiou F, Stewart AF, Dutrillaux B, Losson R, Chambon P (2001) NSD3, a new SET domain-containing gene, maps to 8p12 and is amplified in human breast cancer cell lines. Genomics 74(1):79–88 CrossRefPubMed

18.

Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang Y, Khatry DB, Protopopov A, You MJ, Aguirre AJ et al (2005) High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci USA 102(27):9625–9630 CrossRefPubMedPubMedCentral

19.

Taketani T, Taki T, Nakamura H, Taniwaki M, Masuda J, Hayashi Y (2009) NUP98-NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11) (p11;p15) and expression pattern of NSD family genes. Cancer Genet Cytogenet 190(2):108–112 CrossRefPubMed

20.

Zhou Z, Thomsen R, Kahns S, Nielsen AL (2010) The NSD3L histone methyltransferase regulates cell cycle and cell invasion in breast cancer cells. Biochem Biophys Res Commun 398(3):565–570 CrossRefPubMed

21.

He C, Li F, Zhang J, Wu J, Shi Y (2013) The methyltransferase NSD3 has chromatin-binding motifs, PHD5-C5HCH, that are distinct from other NSD (nuclear receptor SET domain) family members in their histone H3 recognition. J Biol Chem 288(7):4692–4703 CrossRefPubMed

22.

Shen C, Ipsaro JJ, Shi J, Milazzo JP, Wang E, Roe JS, Suzuki Y, Pappin DJ, Joshua-Tor L, Vakoc CR (2015) NSD3-short is an adaptor protein that couples BRD4 to the CHD8 chromatin remodeler. Mol Cell 60(6):847–859 CrossRefPubMedPubMedCentral

23.

Chen Y, McGee J, Chen X, Doman TN, Gong X, Zhang Y, Hamm N, Ma X, Higgs RE, Bhagwat SV et al (2014) Identification of druggable cancer driver genes amplified across TCGA datasets. PLoS ONE 9(5):e98293 CrossRefPubMedPubMedCentral

24.

Luo J, Liu S, Leung S, Gru AA, Tao Y, Hoog J, Ho J, Davies SR, Allred DC, Salavaggione AL et al (2017) An mRNA gene expression-based signature to identify FGFR1-amplified estrogen receptor-positive breast tumors. J Mol Diagn 19(1):147–161 CrossRefPubMed

25.

Yang ZQ, Streicher KL, Ray ME, Abrams J, Ethier SP (2006) Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 66(24):11632–11643 CrossRefPubMed

26.

Cornen S, Guille A, Adelaide J, Addou-Klouche L, Finetti P, Saade MR, Manai M, Carbuccia N, Bekhouche I, Letessier A et al (2014) Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. PLoS ONE 9(1):e81843 CrossRefPubMedPubMedCentral

27.

Andre F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S et al (2013) Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 19(13):3693–3702 CrossRefPubMed

28.

Pearson A, Smyth E, Babina IS, Herrera-Abreu MT, Tarazona N, Peckitt C, Kilgour E, Smith NR, Geh C, Rooney C et al (2016) High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial. Cancer Discov 6(8):838–851 CrossRefPubMedPubMedCentral

Titel: Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3
Autoren:: Brittany Turner-Ivey
Ericka L. Smith
Alex C. Rutkovsky
Laura S. Spruill
Jamie N. Mills
Stephen P. Ethier
Publikationsdatum: 08.05.2017
DOI: https://doi.org/10.1007/s10549-017-4258-9
Verlag: Springer US
Zeitschrift: Breast Cancer Research and Treatment
Ausgabe 2/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217

Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.
Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

18.09.2018 | Mammakarzinom | Nachrichten

Newsletter bestellen

Bildnachweise

e.Med Kampagnen-Visual, Mail Icon II

Development of mammary hyperplasia, dysplasia, and invasive ductal carcinoma in transgenic mice expressing the 8p11 amplicon oncogene NSD3

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Bis zum 22.10. bestellen und 100 € sparen!

e.Med Gynäkologie & Urologie

e.Med Onkologie

Übergewicht schützt vor Brustkrebs vor der Menopause

Immuntherapie wirkt auch gegen Melanommetastasen im Gehirn

Das sind die Gewinner der Ig-Nobelpreise

Mantelzelllymphom: Patienten in Studien am besten aufgehoben

Newsletter

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Bis zum 22.10. bestellen und 100 € sparen!

e.Med Gynäkologie & Urologie

e.Med Onkologie

Weitere Artikel der Ausgabe 2/2017

The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results

Objective breast symmetry analysis with the breast analyzing tool (BAT): improved tool for clinical trials

Preoperative prediction of the size of pure ductal carcinoma in situ using three imaging modalities as compared to histopathological size: does magnetic resonance imaging add value?

Prospective open uncontrolled phase I study to define a well-tolerated dose of oral artesunate as add-on therapy in patients with metastatic breast cancer (ARTIC M33/2)

Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications

A breast cancer gene signature for indolent disease

Neu im Fachgebiet Onkologie

Übergewicht schützt vor Brustkrebs vor der Menopause

Immuntherapie wirkt auch gegen Melanommetastasen im Gehirn

Das sind die Gewinner der Ig-Nobelpreise

Mantelzelllymphom: Patienten in Studien am besten aufgehoben

Newsletter